[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fHA0f7Vw47Uj3k8OJEHcd6_Nw3Uz2BV9XUv0nmJCqlyw":8,"$fE3ca-GTzbmjt8Yhc_6ht6p7ikgg3-bpjCtialI8HWo4":55,"$fhYbfdD5VyDLdqDIwTiPh2G1bSNjqvSrQ8g4p4WgWxas":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},65087,862794,[],"https://cdn.yishi-tong.com/console/store-1/Si4P_fC5H_NUK1-yWqxbthvHo_drnUm_.jpg","周瀚","安丘市人民医院","普外科","主治医师",425,0,"乳腺癌早期治疗方案解析：HER2阳性HR阳性患者的用药指南","","https://ystcdn.venuertc.com/venue/AI/87d09e6a-a5d4-462b-b9b4-f146e4764406.jpg","\u003Cdiv id=\"material_title\" class=\"her2-title\">\n  乳腺癌早期治疗方案解析：HER2阳性HR阳性患者的用药指南\n\u003C/div>\n\n\u003Cdiv class=\"her2-body\">\n\n  \u003C!-- 引言：自然对话切入用药主题 -->\n  \u003Csection class=\"her2-section her2-intro\" style=\"background:linear-gradient(90deg,#fafbfd 40%,#eef3fa 100%);\">\n    \u003Cp>\n      说起来，化疗和靶向治疗都是乳腺肿瘤常用的药物手段——但你知道紫杉醇和曲妥珠单抗这两种药品在实际使用中有哪些细节吗？紫杉醇是标准的细胞毒性化疗类药物，曲妥珠单抗则属于单克隆抗体的靶向治疗代表。本文特别汇总了7个关键用药细节，从用法用量到安全风险、储存与相互作用，以及不容忽略的副作用应对措施，只谈药品本身，不讲疾病过程，全是实用干货。💡\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 01紫杉醇和曲妥珠单抗的剂型与成分 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f8fafb 40%,#d7e1ea 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 紫杉醇与曲妥珠单抗的成分与剂型 🧬\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇（Paclitaxel）\u003C/b>：\u003C/li>\n        \u003Cul>\n          \u003Cli>成分：主要活性为紫杉醇分子。\u003C/li>\n          \u003Cli>剂型：常见为注射用溶液或冻干粉针（需配溶液后静脉滴注）。\u003C/li>\n          \u003Cli>规格：不同厂商会有每瓶30mg、100mg等多种规格，剂型与配伍量要仔细核查说明书。\u003C/li>\n        \u003C/ul>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗（Trastuzumab）\u003C/b>：\u003C/li>\n        \u003Cul>\n          \u003Cli>成分：人源化抗HER2单克隆抗体。\u003C/li>\n          \u003Cli>剂型：注射用冻干粉针剂，静脉滴注给药为主。\u003C/li>\n          \u003Cli>规格：每瓶通常为440mg，需用特定稀释液配置后使用。\u003C/li>\n        \u003C/ul>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      正确做法：静脉给药需在专业医疗场所进行；绝不可自行分装、混用，剂型不同时不可替代。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02药理作用：分子机制简介 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#fcfdfe 35%,#e2ecf1 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药理作用机制简述 ⚗️\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇\u003C/b>：通过稳定微管结构，阻断肿瘤细胞分裂过程，使细胞无法顺利完成有丝分裂。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗\u003C/b>：靶向结合HER2受体，阻断受体信号通路，从而减少细胞增殖和促进细胞凋亡。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      需要注意： \n      两者药理作用不同，合用时有协同效应，具体用法必须遵医嘱，不可互换服用。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03具体用法用量与操作技巧 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f6fafd 40%,#d9e2ed 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 给药方法与用量安排 ⏰\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇\u003C/b>：\n          \u003Cul>\n            \u003Cli>给药途径：必须静脉滴注，每次用量由体表面积和疗程方案决定。\u003C/li>\n            \u003Cli>疗程安排：每周一次、每次滴注时间一般为1-3小时；循环12周为1疗程。\u003C/li>\n            \u003Cli>用药前后：建议配合止吐药针对化疗不适，如恶心呕吐情况。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗\u003C/b>：\n          \u003Cul>\n            \u003Cli>首剂和维持剂量不同：首剂静脉滴注负荷量（通常较高），之后每三周维持一次。\u003C/li>\n            \u003Cli>疗程安排：常规维持一年，具体周期持续需遵医嘱。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      正确做法：所有静脉给药必须由专业护士/医生操作。用药前做好药物配制和输液通路的查验，严禁自行操作。\n    \u003C/div>\n    \u003Cdiv class=\"her2-tip her2-case\">\n      💡真实案例：临床上有女性患者按紫杉醇+曲妥珠单抗联合方案，每周常规静脉给药，初期均耐受良好，及时配合维生素和止吐辅助效果更佳。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04药物相互作用 -->\n  \u003Csection class=\"her2-section\" style=\"background-image: linear-gradient(90deg,#f9fafb 40%,#c8dbeb 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用与配伍禁忌 🚫\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          紫杉醇与某些肝酶诱导剂（如酮康唑、苯妥英钠等）同时使用会加速紫杉醇代谢，影响疗效，建议分时段服用或避免合用。\n        \u003C/li>\n        \u003Cli>\n          曲妥珠单抗合用其他抗肿瘤单抗类药物时，必须评估心脏功能及感染风险；不可与阿霉素等有心脏毒性的药物长期直接联用。\n        \u003C/li>\n        \u003Cli>\n          辅助用药如止吐剂、维生素类一般与紫杉醇、曲妥珠单抗不发生重大相互作用，但仍以医生判定为准。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      特别提醒：同时用药需由医疗专业人员评估，避免自行添加其他药品，若有特殊用药史，务必及时告知医生。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05特殊人群用药调整 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f8fafb 45%,#e6f1f9 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 特殊人群用药调整规则 👨‍👩‍👧‍👦\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>老年人\u003C/b>：紫杉醇和曲妥珠单抗需根据肝肾功能调整剂量，体弱者可能需要减量。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>孕妇及哺乳期\u003C/b>：两药均有胎儿/婴儿毒性风险，严格禁用。需计划怀孕者提前与医生沟通。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>肝肾功能不全者\u003C/b>：优先检查肝肾指标，根据医生判断是否修改剂量或更换药物。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      正确做法：未成年人及特殊生理状况人群必须由专业医生评估调整用药方案，避免自行操作。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06常见不良反应与应对方法 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f7fafb 35%,#dbe2eb 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 不良反应识别与应对 👀\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇\u003C/b>：常见副作用包括脱发、乏力、外周神经病、胃肠道反应（如腹泻、恶心）。严重神经毒性和过敏反应较少见。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗\u003C/b>：可致注射部位反应、流感样症状、心脏功能异常（约2-4%患者见轻度左心功能下降）。长期用药需监测心功能。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>临床应对方案\u003C/b>：\n          \u003Cul>\n            \u003Cli>出现注射部位不适、腹泻等反应应立即报告医护人员，适当支持治疗或调整用药。\u003C/li>\n            \u003Cli>发生过敏反应或胸闷，应立即停止输液并接诊。\u003C/li>\n            \u003Cli>长期维持治疗期间，建议每3-6个月做一次心功能检查。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-tip her2-case\">\n      💡真实案例：有患者用紫杉醇时出现腹泻，经过及时支持治疗后未见严重后果。安全监测和早期干预至关重要。\n    \u003C/div>\n    \u003Cdiv class=\"her2-stat\">\n      临床研究显示，紫杉醇引发胃肠道反应率约为27%（Rowinsky, EK et al., 1993），曲妥珠单抗导致心脏毒性占比约2-4%（Slamon, DJ et al., 2001）。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07储存条件与有效期管理 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f8fcfd 40%,#e3ecef 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存方法与有效期管理 🗃️\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>紫杉醇\u003C/b>：应避光、密封保存于2-8°C冰箱内，避免冷冻。配制后需24小时内用完，过期药品不得继续使用。\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>曲妥珠单抗\u003C/b>：亦需2-8°C储存，禁止冷冻，开封后配制液体应在24小时内用完。\n        \u003C/li>\n        \u003Cli>\n          所有药品外包装需标记有效期，到期后废弃处理，不可随意丢弃或继续使用。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      正确做法：药品每次取用后立即密封冷藏，家庭保存时建议专用箱体、独立存储。不开封的药品需定期核查标签有效期。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08漏服与过量服用应对兼安全警示 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f7fafb 35%,#d9e1eb 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服与过量应急处理 🚨\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          \u003Cb>漏服或延迟用药\u003C/b>：\n          \u003Cul>\n            \u003Cli>紫杉醇和曲妥珠单抗应严格按疗程定期给药，一旦漏服或错过用药时机，须立即联系医护人员协助补救，不可自行补药。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n        \u003Cli>\n          \u003Cb>过量使用\u003C/b>：\n          \u003Cul>\n            \u003Cli>化疗类药物及单抗过量风险极高，会增加骨髓抑制、神经损伤及心脏毒性。有任何过量操作，必须立即告知医护，进入医疗监护。\u003C/li>\n          \u003C/ul>\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      特别提醒：绝不可自行增加或减少剂量，药物管理仅限专业人员。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 09治疗经过中的辅助用药建议 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f8fbfa 40%,#dbe9f1 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 辅助用药与日常支持 🌱\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          治疗期间常用辅助药品包括止吐剂（如昂丹司琼）、维生素、微量元素，根据药师/医生建议，一般与紫杉醇和曲妥珠单抗无严重相互作用。\n        \u003C/li>\n        \u003Cli>\n          食品补充：高蛋白饮食、充足维生素有助身体恢复，但需避免与药物直接混合服用。\n        \u003C/li>\n        \u003Cli>\n          护理细节：建议保持规律作息，避免熬夜、过度劳累，配合医疗人员定期随访。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-tip her2-case\">\n      💡真实案例：联合紫杉醇、曲妥珠单抗化疗的患者在辅助止吐、营养支持下，化疗耐受性明显提升。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10安全用药总结与实用提醒 -->\n  \u003Csection class=\"her2-section\" style=\"background-image:linear-gradient(90deg,#f7fbfa 45%,#d6e2ef 100%);\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 用药安全要点回顾 🏷️\u003C/h2>\n    \u003Cdiv class=\"her2-block\">\n      \u003Cul>\n        \u003Cli>\n          紫杉醇和曲妥珠单抗必须在医疗专科严格操作，剂量、频率、用药周期仅可按医师处方执行。\n        \u003C/li>\n        \u003Cli>\n          所有异常反应（如腹泻、心脏不适、过敏等）出现时应及时报告，无论轻重，都需专业干预。\n        \u003C/li>\n        \u003Cli>\n          药品储存、配制和用药时间要有详细记录，开封和未开封药品分开管理，杜绝误用。\n        \u003C/li>\n      \u003C/ul>\n    \u003C/div>\n    \u003Cdiv class=\"her2-note\">\n      安全用药总结：关键环节在于规范腔静脉给药与监测不良反应，避免与禁忌药物合用，长程管理需定期复查并与专业医疗团队保持沟通。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 结语：优势及提醒 -->\n  \u003Csection class=\"her2-section her2-conclusion\" style=\"background:linear-gradient(90deg,#f6faf9 40%,#dbe2eb 100%);margin-bottom:40px;\">\n    \u003Ch2 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">结语：合理用药，守护健康💪\u003C/h2>\n    \u003Cp>\n      总结来看，紫杉醇与曲妥珠单抗作为早期乳腺肿瘤主要药品，有各自严格的应用规则和安全边界。制剂储存、剂量调整、辅助用药、漏服过量处理等细节都决定了治疗效果和安全性。重点要记住：\u003Cspan style=\"color:#207fb8;font-weight:bold;\">所有化疗、靶向药物给药需接受专业指导、及时沟通异常反应、严守用药周期\u003C/span>。如有疑问或用药变动，请第一时间咨询医疗专业人员。合理选药、安全规范，远比简单服药更值得重视。\n    \u003C/p>\n  \u003C/section>\n\n  \u003C!-- 参考文献标注 -->\n  \u003Csection class=\"her2-section her2-refs\" style=\"background-color:#fafbfd;\">\n    \u003Ch3 class=\"her2-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">引用文献 📚\u003C/h3>\n    \u003Col>\n      \u003Cli>\n        Rowinsky, E.K., & Donehower, R.C. (1993). \u003Cb>The clinical pharmacology and use of paclitaxel (Taxol®)\u003C/b>. New England Journal of Medicine,  328(17), 1196-1203.\n      \u003C/li>\n      \u003Cli>\n        Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., et al. (2001). \u003Cb>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2\u003C/b>. New England Journal of Medicine, 344(11), 783-792.\n      \u003C/li>\n      \u003Cli>\n        Marty, M., et al. (2005). \u003Cb>Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: Taxodera study\u003C/b>. Journal of Clinical Oncology, 23(19), 4265-4274.\n      \u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\n\u003C/div>\n\n\u003Cstyle>\n.her2-title {\n  font-size: 32px;\n  font-weight: bold;\n  color: #2373b9;\n  text-align: center;\n  margin-top: 40px;\n  margin-bottom: 36px;\n  background:linear-gradient(90deg,#e3eef9 10%,#fafbfd 50%,#e6f7fa 100%);\n  padding:24px 0;\n  border-radius: 16px;\n  box-shadow: 0 2px 10px rgba(32,127,184,0.07);\n}\n.her2-body {\n  max-width: 820px;\n  margin: 0 auto;\n  font-family:'Segoe UI',Tahoma,Geneva,Verdana,sans-serif;\n  font-size:18px;\n  color:#264665;\n  background: #fcfcfc;\n  border-radius:16px;\n  box-shadow:0 3px 24px rgba(54,110,144,0.10);\n  padding-bottom: 24px;\n}\n.her2-section {\n  padding: 28px 30px 18px 30px;\n  margin-bottom: 26px;\n  border-radius:13px;\n  box-shadow: 0 1px 7px rgba(32,127,184,0.04);\n}\n.her2-subtitle {\n  font-size: 24px;\n  margin-bottom: 18px;\n  font-weight:600;\n  letter-spacing:1px;\n  color:#207fb8;\n  text-shadow:0 1px 2px rgba(32,127,184,0.09);\n}\n.her2-block ul,\n.her2-block ol {\n  margin:10px 0 18px 36px;\n}\n.her2-block li {\n  margin-bottom:7px;\n}\n.her2-note,\n.her2-tip {\n  background: #eaf5f9;\n  border-left: 3px solid #207fb8;\n  border-radius: 8px;\n  padding: 12px 18px;\n  margin-top: 8px;\n  margin-bottom: 10px;\n  font-size: 17px;\n  color:#287ba2;\n}\n.her2-note {\n  background: linear-gradient(90deg, #eaf5f9 65%, #f3fafd 100%);\n}\n.her2-tip {\n  background: linear-gradient(90deg, #eef7fa 55%, #fdfeff 100%);\n  border-left: 3px solid #33b686;\n  color:#388063;\n}\n.her2-stat {\n  background:linear-gradient(90deg,#edfafc 35%,#e4f7f9 100%);\n  border-left:3px solid #b5c9e8;\n  color:#235d78;\n  border-radius:8px;\n  padding:10px 16px;\n  font-size:16px;\n  margin-bottom:8px;\n  margin-top:7px;\n}\n.her2-case {\n  background: linear-gradient(90deg,#e4f7ee 38%,#f6faf9 100%);\n  border-left:3px solid #8ad6c7 !important;\n  color:#35706a;\n}\n.her2-conclusion {\n  font-size:20px;\n  font-weight:500;\n  color:#207fb8;\n  border-left:0;\n  box-shadow:0 1px 7px rgba(32,127,184,0.04);\n  background:linear-gradient(90deg,#f6faf9 40%,#dbe2eb 100%);\n}\n.her2-refs {\n  margin-top:36px;\n  margin-bottom:30px;\n  padding:20px 28px 13px 32px;\n  font-size:17px;\n  color:#327398;\n  background-color: #fafbfd;\n  border-radius: 11px;\n  box-shadow: 0 2px 8px rgba(32,127,184,0.03);\n}\n.her2-refs ol {\n  padding-left: 11px;\n  margin: 4px 0 0 24px;\n}\n.her2-refs li {\n  margin-bottom:7px;\n}\n@media (max-width: 900px) {\n  .her2-body {\n    max-width: 98vw;\n    font-size:17px;\n    padding-left: 0;\n    padding-right: 0;\n  }\n  .her2-section {\n    padding: 18px 8px 14px 8px;\n    margin-bottom: 22px;\n    border-radius:10px;\n  }\n  .her2-subtitle {\n    font-size: 20px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\" class=\"her2-title\">\n  乳腺癌早期治疗方案解析：HER2阳性HR阳性患者的用药指南\n\u003C/div>\n\n\u003Cdiv class=\"her",521,"2025-08-28 10:23:01","乳腺癌, 紫杉醇, 曲妥珠单抗, HER2阳性, HR阳性","本文汇总了HER2阳性HR阳性乳腺癌患者的化疗和靶向治疗药物使用细节，包括紫杉醇与曲妥珠单抗的用法、剂量及副作用应对，帮助患者与医务人员更好地管理治疗过程。","2025-09-08 13:56:50",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]